Share of Clicks for top 10 US Pharma & Biotech Pharmacology brands
Here are the Top 10 competitors in the industry by Share of Clicks for the last month.
| Domain | Share of clicks |
|---|---|
| lilly.com | 24.58 |
| ro.co | 12.9 |
| forbes.com | 5.78 |
| wegovy.com | 4.18 |
| bmimd.com | 3.09 |
| goodrx.com | 2.87 |
| goodlifemeds.com | 2.74 |
| webmd.com | 2.68 |
| telyrx.com | 2.4 |
| repatha.com | 2.02 |
| others | 36.76 |
- lilly.com - 24.58%
- ro.co - 12.9%
- forbes.com - 5.78%
- wegovy.com - 4.18%
- bmimd.com - 3.09%
- goodrx.com - 2.87%
- goodlifemeds.com - 2.74%
- webmd.com - 2.68%
- telyrx.com - 2.4%
- repatha.com - 2.02%
- others - 36.76%
Copyright © Adthena. All rights reserved.
In the competitive landscape of Google PPC, Lilly.com leads with a 24.58% click share, followed by Ro.co at 12.9%. Others collectively dominate with 36.76%, showcasing diverse competition.
Share of Spend for the top 10 US Pharma & Biotech Pharmacology brands
Curious about your market position? Here you can see the Top 10 competitors in the industry by Share of Spend for the last month.
| Date | lilly.com | ro.co | forbes.com | webmd.com | biktarvy.com | goodlifemeds.com | repatha.com | bmimd.com | goodrx.com | maxlife.com |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/09/01 | 25.44% | 20.39% | 4.71% | 3.57% | 1.26% | 5.37% | 0.5% | 5.57% | 1.22% | 2.2% |
| 2026/09/02 | 27.97% | 15.79% | 9.61% | 3.6% | 0.48% | 2.64% | 0.51% | 7.43% | 1.41% | 0.47% |
| 2026/09/03 | 27.86% | 18.87% | 2.95% | 6.66% | 0.62% | 1.72% | 0.72% | 7.64% | 1.04% | 0.57% |
| 2026/09/04 | 31.37% | 14.02% | 9.52% | 1.16% | 0.56% | 4.75% | 0.32% | 3.82% | 1.97% | 0.52% |
| 2026/09/05 | 35.56% | 14.89% | 6.01% | 0.43% | 0.75% | 3.41% | 1.2% | 6.89% | 0.8% | 0.98% |
| 2026/09/06 | 31.1% | 17.34% | 0.97% | 0.93% | 1.73% | 4.18% | 1.56% | 7.36% | 1.23% | 0.62% |
| 2026/09/07 | 33.18% | 13.57% | 6.09% | 2.56% | 2.73% | 0.91% | 1.4% | 5.51% | 1.62% | 0.48% |
| 2026/09/08 | 17.05% | 19.62% | 8.64% | 5.17% | 1.61% | 2.71% | 1.27% | 5.96% | 3.35% | 0.69% |
| 2026/09/09 | 20.78% | 18.21% | 6.48% | 4.28% | 2.44% | 8.03% | 0.79% | 1.65% | 1.3% | 10.41% |
| 2026/09/10 | 21.92% | 16.87% | 8.47% | 0.64% | 3.54% | 5.39% | 1.25% | 2.94% | 1.19% | 6.58% |
| 2026/09/11 | 19.96% | 9.96% | 4.55% | 2.62% | 3.77% | 4.76% | 1.71% | 6.78% | 1.96% | 2.02% |
| 2026/09/12 | 28.35% | 12.87% | 4.14% | 1.12% | 4.2% | 3.76% | 2.95% | 1.99% | 2.92% | 3.54% |
| 2026/09/13 | 22.14% | 8.41% | 4.42% | 1.51% | 3.05% | 10.29% | 1.68% | 7.68% | 2.34% | 4.34% |
| 2026/09/14 | 34.59% | 12.35% | 4.93% | 1.63% | 4.82% | 2.3% | 2.87% | 2.56% | 1.78% | 0.18% |
| 2026/09/15 | 30.8% | 16.92% | 7.21% | 1.54% | 3.97% | 0.36% | 2.9% | 1.32% | 1.96% | 0.34% |
| 2026/09/16 | 22.5% | 13.23% | 3.19% | 4.38% | 3.5% | 10.97% | 1.49% | 3.6% | 1.85% | 9.19% |
| 2026/09/17 | 31.18% | 13.77% | 12.08% | 4.23% | 4.03% | 0.45% | 1.13% | 1.06% | 2.63% | 0.31% |
| 2026/09/18 | 31.91% | 12.82% | 8.15% | 6.36% | 3.83% | 2.29% | 1.46% | 3.15% | 1.89% | 0.47% |
| 2026/09/19 | 24.51% | 13.97% | 4.83% | 4.95% | 3.77% | 4.74% | 2.29% | 6.23% | 1.77% | 0.32% |
| 2026/09/20 | 29.39% | 11.68% | 4.97% | 0.53% | 4.22% | 2.48% | 2.12% | 7.3% | 2.01% | 0.21% |
| 2026/09/21 | 35.48% | 10.08% | 5.52% | 1.09% | 4.69% | 0.91% | 2.12% | 2.79% | 1.98% | 0.31% |
| 2026/09/22 | 26.59% | 18.3% | 5.69% | 1.75% | 4.93% | 0.73% | 2.21% | 0.8% | 1.92% | 0.13% |
| 2026/09/23 | 20.7% | 18.24% | 5.32% | 4.7% | 3.21% | 2.93% | 1.93% | 4.49% | 1.46% | 0.09% |
| 2026/09/24 | 24.5% | 19.42% | 7.23% | 5.08% | 4.31% | 0.46% | 2.55% | 0.74% | 1.34% | 0.07% |
| 2026/09/25 | 29.98% | 19% | 4.13% | 0.66% | 4.75% | 3.92% | 2.05% | 2.93% | 1.78% | 0.15% |
| 2026/09/26 | 20.02% | 10.35% | 11.38% | 3.55% | 5.65% | 2.36% | 2.78% | 3.09% | 1.87% | 0.08% |
| 2026/09/27 | 22.84% | 15.01% | 6.2% | 3.12% | 4.67% | 0.3% | 2.87% | 1.23% | 1.51% | 0.09% |
| 2026/09/28 | 26.13% | 13.13% | 6.14% | 7.04% | 5.19% | 0.58% | 2.45% | 0.82% | 0.9% | 0.06% |
| 2026/09/29 | 33.25% | 14.12% | 8.53% | 1.32% | 5.26% | 0.27% | 1.82% | 0.48% | 2.33% | 0% |
| 2026/09/30 | 25.41% | 10.49% | 7.41% | 6.33% | 4.68% | 2.23% | 1.46% | 1.12% | 0.67% | 0.1% |
- lilly.com
- ro.co
- forbes.com
- webmd.com
- biktarvy.com
- goodlifemeds.com
- repatha.com
- bmimd.com
- goodrx.com
- maxlife.com
Copyright © Adthena. All rights reserved.
Lilly.com dominated September with fluctuating spend, peaking mid-month. Ro.co saw a decline, while Forbes.com and WebMD had sporadic spikes. Biktarvy.com and Goodlifemeds.com showed steady growth. Maxlife.com ended with minimal activity.
Competitor Count for US Pharma & Biotech Pharmacology
Ever wondered how many competitors you’re up against in your industry? Well look no further, here we can see the number of advertisers bidding over the last month.
| Date | Competitor Count |
|---|---|
| 2026/09/01 | 342 |
| 2026/09/02 | 351 |
| 2026/09/03 | 359 |
| 2026/09/04 | 369 |
| 2026/09/05 | 375 |
| 2026/09/06 | 384 |
| 2026/09/07 | 388 |
| 2026/09/08 | 388 |
| 2026/09/09 | 375 |
| 2026/09/10 | 374 |
| 2026/09/11 | 373 |
| 2026/09/12 | 390 |
| 2026/09/13 | 385 |
| 2026/09/14 | 384 |
| 2026/09/15 | 392 |
| 2026/09/16 | 390 |
| 2026/09/17 | 379 |
| 2026/09/18 | 397 |
| 2026/09/19 | 397 |
| 2026/09/20 | 380 |
| 2026/09/21 | 393 |
| 2026/09/22 | 389 |
| 2026/09/23 | 380 |
| 2026/09/24 | 379 |
| 2026/09/25 | 382 |
| 2026/09/26 | 400 |
| 2026/09/27 | 376 |
| 2026/09/28 | 382 |
| 2026/09/29 | 387 |
| 2026/09/30 | 384 |
Copyright © Adthena. All rights reserved.
September saw a dynamic shift in distinct advertisers, starting at 342 and peaking at 400 mid-month. The month concluded with a slight dip, ending at 384.
